Published in Lancet on March 12, 1977
Prevalence of hepatitis A and B infections in multiply transfused thalassaemic patients. Br Med J (1978) 1.13
Viral exposure and abnormal liver function in haemophilia. J Clin Pathol (1979) 0.91
Serological markers for hepatitis types A and B among U.S. Arym soldiers, Germany. Am J Public Health (1979) 0.87
Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol (2014) 0.87
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol (1993) 8.47
Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science (1997) 7.53
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36
A colour test for the measurement of antibody to certain mycoplasma species based upon the inhibition of acid production. J Hyg (Lond) (1966) 6.23
Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science (1973) 5.82
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol (2000) 5.26
Lack of protective immunity against reinfection with hepatitis C virus. Science (1992) 4.94
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Identification of a highly conserved sequence element at the 3' terminus of hepatitis C virus genome RNA. J Virol (1996) 4.59
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A (1993) 4.30
Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med (1991) 4.24
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology (1994) 4.01
Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1989) 3.67
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
A microtiter solid-phase radioimmunoassay for hepatitis A antigen and antibody. J Immunol (1976) 3.53
Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol (1993) 3.37
Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med (1975) 3.31
Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet (1980) 3.31
Australia antigen: large-scale purification from human serum and biochemical studies of its proteins. J Virol (1971) 3.28
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. J Clin Microbiol (1989) 3.19
Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect Immun (1981) 3.18
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol (1994) 3.06
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med (1992) 3.01
Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome. Exp Neurol (1989) 3.00
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J Immunol (1971) 2.98
Microtiter solid-phase radioimmunoassay for hepatitis B antigen. Appl Microbiol (1973) 2.96
HLA class II antibodies in transfusion-related acute lung injury. Transfusion (2001) 2.93
Molecular cloning and characterization of hepatitis A virus cDNA. Proc Natl Acad Sci U S A (1983) 2.92
Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol (1987) 2.83
A color test for the measurement of antibody to the non-acid-forming human Mycoplasma species. Am J Epidemiol (1966) 2.81
Transmissible agent in non-A, non-B hepatitis. Lancet (1978) 2.78
Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science (1979) 2.78
Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med (1989) 2.77
Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis (1987) 2.68
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
Enzyme-linked immunosorbent assay for detection of hepatitis A antigen in stool and antibody to hepatitis A antigen in sera: comparison with solid-phase radioimmunoassay, immune electron microscopy, and immune adherence hemagglutination assay. J Clin Microbiol (1978) 2.64
What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? Lancet (1989) 2.63
Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol (1982) 2.62
Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med (1995) 2.61
Detection of flaviviruses by reverse-transcriptase polymerase chain reaction. J Med Virol (1991) 2.59
The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. N Engl J Med (1989) 2.58
Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med (1982) 2.58
A complement-fixation test for measuring Australia antigen and antibody. J Infect Dis (1969) 2.58
Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A (1987) 2.56
Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology (1983) 2.56
Biophysical properties of Australia antigen. J Virol (1969) 2.45
Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology (1996) 2.44
Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis (1975) 2.41
Clinical and serological analysis of transfusion-associated hepatitis. Lancet (1975) 2.41
Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology (2001) 2.38
Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination. J Virol (1991) 2.36
Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J (1996) 2.35
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Circulating immune complexes and complement activation in primary biliary cirrhosis. N Engl J Med (1978) 2.30
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Purification of hepatitis A antigen from feces and detection of antigen and antibody by immune adherence hemagglutination. Infect Immun (1976) 2.27
Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med (1986) 2.27
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis (1978) 2.21
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Further studies on a "new" human isoprecipitin system (Australia antigen). Blood (1966) 2.16
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology (1998) 2.06
High frequency of antibodies to Mycoplasma penetrans in HIV-infected patients. Lancet (1992) 2.06
Transfusion-associated graft-versus-host disease. Vox Sang (2008) 2.05
A comparison of the frequency of hepatitis-B antigen and antibody in hospital and nonhospital personnel. N Engl J Med (1973) 2.05
Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A (1990) 2.04